{
    "nct_id": "NCT00164749",
    "title": "A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2008-04-25",
    "description_brief": "The purpose of this study is to develop procedures for testing the effectiveness of curcumin on slowing Alzheimer's disease (AD) progression.",
    "description_detailed": "A double-blind, randomized, clinical trial of 30 subjects will be carried out to develop procedures for testing the effectiveness of curcumin on slowing Alzheimer's disease (AD) progression. Curcumin is a polyphenolic molecule extracted from turmeric and is widely and safely used as a yellow food coloring. Because of its strong anti-inflammatory activity, curcumin was tested in animal models of AD, where it significantly reduced levels of brain amyloid, oxidized proteins, and isoprostanes, and prevented cognitive deficits. AD patients will receive placebo, 1 g, or 4 g of curcumin daily for six months. All patients will also receive 120 mg ginkgo leaf extract daily. At 0, 1, 3, and 6 months of the study, a cognitive test will be performed, and blood samples will be analyzed for levels of isoprostane, amyloid beta protein, metals, and cholesterol. Curcumin and its metabolites will be measured in blood at 1 month. The primary objective for this first human study of curcumin in AD is to examine safety and procedures for a possible larger trial testing curcumin against AD. The secondary objective is to determine whether curcumin affects biochemical measures, and, if so, which dose is most effective. The tertiary objective is to determine whether curcumin slows cognitive decline in AD. This study may lead to inexpensive treatment that delays progression of AD.",
    "phase": [
        "PHASE1",
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "Curcumin (polyphenol from turmeric)",
        "Ginkgo biloba extract (EGb)"
    ],
    "placebo": [
        "Not specified in the provided description"
    ],
    "explanation_target": [
        "Reason: The study purpose states it aims to test curcumin for \"slowing Alzheimer's disease (AD) progression,\" which indicates an intent to modify disease pathology rather than only treat symptoms. Curcumin is a small-molecule polyphenol (not a biologic) reported to act on AD-related pathology (inhibits amyloid-\u03b2 aggregation, affects tau phosphorylation/clearance, anti-inflammatory/antioxidant effects). \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search8\ue201",
        "Act: Identified interventions from the title/description \u2014 curcumin and ginkgo. Curcumin is a small-molecule polyphenol with proposed anti-amyloid, anti-tau and neuroprotective mechanisms (disease-targeted). Ginkgo biloba is an herbal extract commonly studied as a cognitive enhancer/neuroprotective agent; clinical reviews/meta-analyses show mixed but sometimes modest cognitive benefits in AD. Given the study aim (slowing progression) and that both interventions are non-biologic small molecules/plant extracts, the best matching category is \"disease-targeted small molecule.\" \ue200cite\ue202turn0search2\ue202turn0search3\ue202turn0search1\ue202turn0search5\ue201",
        "Reflect: Alternative interpretation \u2014 Ginkgo is often considered a cognitive enhancer (symptomatic benefit) rather than a direct disease-modifying biologic. However, because the study explicitly aims to test curcumin for slowing progression (disease modification) and both agents are small-molecule/plant-extract interventions (not monoclonal antibodies or vaccines), the \"disease-targeted small molecule\" category best fits. I note ambiguity: if the trial's primary endpoint were purely symptomatic cognitive scores with no disease-pathology endpoints, one could argue for \"cognitive enhancer,\" but the stated goal (slowing progression) supports disease-targeted small molecule classification. \ue200cite\ue202turn0search7\ue202turn0search9\ue201",
        "Web search results used (key sources): 1) Review summarizing mechanisms of curcumin in AD (anti-amyloid, anti-tau, anti-inflammatory, antioxidant). \ue200cite\ue202turn0search2\ue202turn0search3\ue201 2) Curcumin described as a polyphenol/small molecule from turmeric. \ue200cite\ue202turn0search8\ue201 3) Systematic reviews/meta-analyses and overviews on Ginkgo biloba in AD (mixed evidence; some modest cognitive benefit in some trials). \ue200cite\ue202turn0search1\ue202turn0search5\ue201 4) NCCIH summary noting inconclusive evidence for Ginkgo in preventing or slowing dementia but reporting some trial-level effects. \ue200cite\ue202turn0search7\ue201"
    ],
    "agent_type": "R) Multi-target",
    "explanation_agent": [
        "Reason: The trial tests curcumin (a polyphenol) and Ginkgo biloba extract \u2014 both are small-molecule/plant-extract interventions reported to act on multiple Alzheimer\u2019s-related pathways: curcumin has published anti\u2011amyloid (inhibits A\u03b2 aggregation and can bind plaques), anti\u2011tau, anti\u2011inflammatory and antioxidant effects; Ginkgo has been studied as a cognitive enhancer/neuroprotective agent with antioxidant, anti\u2011inflammatory and possible vascular/cerebral blood\u2011flow effects. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search5\ue202turn1search0\ue202turn0search3\ue201.",
        "Act: From the description the interventions are curcumin and Ginkgo (EGb extracts). Because curcumin\u2019s reported mechanisms span amyloid, tau, inflammation and oxidative\u2011stress pathways, and Ginkgo\u2019s effects are likewise pleiotropic (cognition/vascular/antioxidant/inflammatory), the trial does not map cleanly to a single CADRO mechanism (A, B, F, G, K, etc.). Per the instructions, when multiple targets/mechanisms are indicated, assign R) Multi\u2011target. Key supporting sources: a PubMed/Alzheimer model study and reviews of curcumin\u2019s anti\u2011amyloid and multi\u2011mechanistic actions, and systematic reviews/meta\u2011analyses and NCCIH synthesis for Ginkgo. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search5\ue202turn1search0\ue202turn0search3\ue201.",
        "Reflect: Classification check \u2014 curcumin could individually fit A) Amyloid beta and B) Tau and also F) Inflammation/G) Oxidative Stress; Ginkgo could fit M) Synaptic plasticity/neuroprotection or K) Vasculature or F/G. Because both compounds are described as acting on several Alzheimer\u2019s\u2011relevant pathways and the study aims at disease modification, the most specific CADRO choice is R) Multi\u2011target rather than forcing one single pathology category. If the trial description had explicitly stated a single primary molecular target (e.g., an anti\u2011A\u03b2 monoclonal antibody), a single CADRO category would be chosen; that is not the case here. \ue200cite\ue202turn0search2\ue202turn1search0\ue201.",
        "Output: R) Multi-target \u2014 Both curcumin and Ginkgo biloba extracts have multiple reported mechanisms (anti\u2011amyloid, anti\u2011tau, anti\u2011inflammatory, antioxidant, vascular/neuroprotective), so the trial best fits CADRO category R) Multi\u2011target rather than a single\u2011pathway category.",
        "Web search results used (key sources cited above):",
        "- Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo (PubMed). \ue200cite\ue202turn0search0\ue201.",
        "- REVIEW: Curcumin and Alzheimer's Disease (PMC review). \ue200cite\ue202turn0search2\ue201.",
        "- Action Mechanisms of Curcumin in Alzheimer\u2019s Disease (MDPI review summarizing anti\u2011amyloid, anti\u2011tau, anti\u2011inflammatory effects). \ue200cite\ue202turn0search5\ue201.",
        "- Efficacy and tolerability of Ginkgo biloba extract EGb 761 in dementia: systematic review and meta\u2011analysis. \ue200cite\ue202turn1search0\ue201.",
        "- NCCIH clinical digest on dietary supplements and cognitive function (summary on Ginkgo evidence). \ue200cite\ue202turn0search3\ue201."
    ]
}